Jaguar Health (JAGX) Income from Non-Controlling Interests (2022 - 2026)
Jaguar Health's (JAGX) quarterly Income from Non-Controlling Interests came in at -$126000.0 in Q1 2026, up 4.55% year-on-year from -$120521.7 in Q1 2025, and up 4.55% on a QoQ basis from -$132000.0 in Q1 2025.
Jaguar Health (JAGX) Income from Non-Controlling Interests (2022 - 2026) Analysis & Trends
Jaguar Health (JAGX) has 5 years of Income from Non-Controlling Interests data on file, last reported at -$126000.0 in Q1 2026.
- On a quarterly basis, Income from Non-Controlling Interests rose 4.55% year-over-year to -$126000.0 in Q1 2026; TTM through Mar 2026 was -$536000.0, a 2.37% increase from a year earlier, with the FY2025 full-year figure at -$563000.0, up 25.82% from the prior year.
- Income from Non-Controlling Interests for Q1 2026 stood at -$126000.0, up from -$132000.0 in the prior quarter.
- Over the last five years, Income from Non-Controlling Interests for JAGX reached as high as -$23000.0 in Q2 2022 and fell as low as -$651000.0 in Q4 2022.
- Historically, Income from Non-Controlling Interests has averaged -$173166.7 across 5 years, with a median of -$137500.0 in 2023.
- On a YoY basis, Income from Non-Controlling Interests climbed as much as 78.65% in 2023 and fell as far as 513.04% in 2023.
- Year by year, Income from Non-Controlling Interests stood at -$651000.0 in 2022, then soared by 78.65% to -$139000.0 in 2023, then increased by 2.16% to -$136000.0 in 2024, then gained by 2.94% to -$132000.0 in 2025, then gained by 4.55% to -$126000.0 in 2026.
- Per Business Quant data, the three most recent Income from Non-Controlling Interests figures were -$126000.0 in Q1 2026, -$132000.0 in Q1 2025, and -$136000.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Nanobiotix | 1,785.82 Bn | 1,785.76 Bn | - | - |
| 2 | Akari Therapeutics | 979.03 Bn | 979.03 Bn | - | - |
| 3 | BeOne Medicines | 473.37 Bn | 468.58 Bn | 1.35 Bn | - |
| 4 | Vertex Pharmaceuticals | 123.58 Bn | 116.33 Bn | 2.59 Bn | - |
| 5 | Regeneron Pharmaceuticals | 71.54 Bn | 62.78 Bn | 3.31 Bn | - |
| 6 | Belite Bio | 62.17 Bn | 62.17 Bn | - | - |
| 7 | Argenx Se | 54.63 Bn | 49.44 Bn | 1.41 Bn | - |
| 8 | Alnylam Pharmaceuticals | 38.11 Bn | 35.10 Bn | 959.66 Mn | - |
| 9 | Revolution Medicines | 36.17 Bn | 36.17 Bn | - | - |
| 10 | Jaguar Health | 523,524.81 | -9.54 Mn | 19.11 Mn | -126,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -126,000.00 |
| Mar 31, 2025 | -132,000.00 |
| Jun 30, 2024 | -136,000.00 |
| Mar 31, 2024 | -142,000.00 |
| Dec 31, 2023 | -139,000.00 |
| Sep 30, 2023 | -126,000.00 |
| Jun 30, 2023 | -141,000.00 |
| Mar 31, 2023 | -195,000.00 |
| Dec 31, 2022 | -651,000.00 |
| Sep 30, 2022 | -89,000.00 |
| Jun 30, 2022 | -23,000.00 |
| Mar 31, 2022 | -178,000.00 |